News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Daily News PCI Doesn’t Cut Arrhythmias in Severe LV Dysfunction: REVIVED-BCIS2 Analysis Todd Neale August 14, 2023
News Daily News Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes Michael O'Riordan June 23, 2023
News Conference News ESC Heart Failure 2023 Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial Shelley Wood May 23, 2023
News Conference News EHRA 2023 Synchronized LV Pacing Not Superior to Conventional CRT in Heart Failure Michael O'Riordan April 18, 2023
News Daily News Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data Michael O'Riordan March 29, 2023
News Conference News THT 2023 High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF Todd Neale March 23, 2023
News Features Heart Failure Care Has a Pipeline Problem: What’s the Fix? Shelley Wood December 20, 2022
News Conference News AHA 2022 IRONMAN Misses but Lends Support to IV Iron Repletion in HF Shelley Wood November 05, 2022
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Daily News Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive Michael O'Riordan September 09, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Daily News AHA Urges More Home-Based Dialysis in Advanced Kidney Failure Michael O'Riordan August 18, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022